NR4A1 and breast carcinoma: While multiple PI3K inhibitors are currently in clinical trials on solid tumors [42], an alpha-specific PI3K inhibitor has been approved for use, in combination with an endocrine therapy, to treat hormone receptor-positive (HER2)‐negative advanced breast cancer [43].